Associated Papers
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA et al.
Cell Stem Cell, 2024
38917807 (PubMed )
Supplement: mmc3.xlsx › Table_S2b
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y et al.
Nature Communications, 2024
38418452 (PubMed )
Supplement: 41467_2024_46134_MOESM5_ESM.xlsx › Supplementary_Data_2
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL.
Ricard L et al.
Frontiers in Immunology, 2024
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37732181 (PubMed )
Supplement: media-2.xlsx › Table_S3
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf
Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality.
Kiefer KC et al.
Esc Heart Failure, 2021
33779075 (PubMed )
Supplement: EHF2-8-1873-s002.xlsx › Sheet1
Rare and novel RUNX1 fusions in myeloid neoplasms: A single-institute experience.
Aypar U et al.
Genes, Chromosomes & Cancer, 2021
Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies.
Li Z et al.
Clinical and Translational Medicine, 2020
33252848 (PubMed )
Supplement: CTM2-10-e222-s003.xlsx › Sheet1
SET Domain Containing 2 Deficiency in Myelodysplastic Syndrome.
Li J et al.
Frontiers in Genetics, 2020
32849799 (PubMed )
Supplement: Presentation_1.pdf
Select a paper to view details